Paul B Manning

Paul B Manning has an estimated net worth of $452 Million. This is based on reported shares across multiple companies, which include Liquidia Corp, Verrica Pharmaceuticals Inc., Taysha Gene Therapies, Inc., Acumen Pharmaceuticals, Inc., AveXis, Inc., Candel Therapeutics, Inc., Dova Pharmaceuticals Inc., Pasithea Therapeutics Corp., and PERRIGO CO.

2018 was Paul B Manning's most active year for acquiring shares with 28 total transactions. Paul B Manning's most active month to acquire stocks was the month of October. 2018 was Paul B Manning's most active year for disposing of shares, totalling 11 transactions. Paul B Manning's most active month to dispose stocks was the month of April. 2023 saw Paul B Manning paying a total of $17,987,003.10 for 17,080,237 shares, this is the most they've acquired in one year. In 2019 Paul B Manning cashed out on 14,762,242 shares for a total of $405,961,655.00, their largest year based on trade value.